1 to 10 of 104
Sort by

Library Entry
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. There is a paucity of data regarding effective therapy for patients whose disease is refractory to PD-1 pathway blockade. This retrospective case series describes a heterogeneous group of patients...

Library Entry
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article concluding that DC vaccines are a safe and reliable platform for promoting antitumor immunity. This combination with one month of high dose IFNα did not improve outcomes. Immune biomarker analysis in the blood...

Library Entry
Immunotherapy for the Treatment of Melanoma-2nd Edition

Published in partnership with the Society for Immunotherapy of Cancer (SITC), this Patient Resource Guide provides current, medically accurate information intended specifically for patients with melanoma and their caregivers. Immunotherapy for the Treatment of Melanoma: Patient Resource Guide ...

Immunotherapy for the Treatment of Melanoma-2nd Edition.pdf

Library Entry
Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report of a patient developing an atypical pattern of response, marked by bone pseudoprogression during therapy with nivolumab for advanced CSCC, followed by sustained response. Authors: Leandro J. C. Oliveira , Aline B....

Library Entry
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case study which describes a patient who developed a basal cell carcinoma during treatment of metastatic NSCLC with the anti PD-1 mAb nivolumab. Authors: Francesco Sabbatino, Antonio Marra , Luigi Liguori , Giosuè...